An interesting conversation took place this week between Ezra Klein (Washington Post), Kevin Outterson (The Incidental Economist), and Megan McArdle (The Atlantic) on the emergence of drug-resistant bacteria

The Sweden-based antibiotic resistance network ReAct has released video highlights and power point presentations from a recent European parliament seminar, “The beginning of a new era in antibiotic development: Shaping of a new business model for life-saving innovation.”  Moderated by Andrew Jack of the Financial Times, the seminar provided a forum to examine new mechanisms to incentivize antibiotic development while also encouraging prudent drug use (i.e.

On Friday the National Institutes of Health (NIH) hosted a public meeting of TATFAR, or the Trans Atlantic Task Force on Antimicrobial Resistance.  I attended, interested to observe this stakeholder discussion of antibiotic resistance and policies to alleviate the problem.

This summer’s media coverage of the NDM-1 gene brought “superbugs” back to the public’s attention. The discovery of NDM-1, which confers resistance to a range of antibiotics, drew comparisons with MRSA and inspired a bold piece by The Guardian on the prospect of a not-so-distant future without antibiotics.

 The following is a guest post from Jo of Head Nurse, who calls it "a simple guide to antibiotic resistance for the liberal arts major."

I was happy to see the New York Times writing about drug resistance and overuse of antibiotics yesterday. If you haven’t seen it yet: Free Antibiotics May Contribute to Drug Resistance, Officials Say. The content is good, the title less so. The title of the related blog post, Are Free Antibiotics Good for You? is even more misleading.

Paul Miller and Michael Dunne are scientists. Dr. Miller is a microbiologist whose training focused on understanding how the genes of bacteria work.